The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 28, Nanjing Noring Biotechnology Co., Ltd. (abbreviation: Noring Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CCB International as its sole sponsor. According to the prospectus, Norling Biotech was incorporated in 2018 to operate in the gas cardiopulmonary equipment market, focusing on the development and commercial application of nitric oxide inhalation (iNO) therapy. As of the last practical date, the company has 5 approved products (including a core product, InoWall) and 5 candidate products under development, covering intensive care, ward, outpatient and home disease management in the field of cardiopulmonary diagnosis and treatment, including three product lines: (i) iNO therapy; (ii) cardiopulmonary circulation support; and (iii) breath diagnosis.

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 28, Nanjing Noring Biotechnology Co., Ltd. (abbreviation: Noring Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CCB International as its sole sponsor. According to the prospectus, Norling Biotech was incorporated in 2018 to operate in the gas cardiopulmonary equipment market, focusing on the development and commercial application of nitric oxide inhalation (iNO) therapy. As of the last practical date, the company has 5 approved products (including a core product, InoWall) and 5 candidate products under development, covering intensive care, ward, outpatient and home disease management in the field of cardiopulmonary diagnosis and treatment, including three product lines: (i) iNO therapy; (ii) cardiopulmonary circulation support; and (iii) breath diagnosis.